Wockhardt posts profit of Rs 82 crore in Q2
New Delhi: Wockhardt Ltd has reported a strong turnaround in its quarterly performance, posting a consolidated profit after tax of Rs 82 crore for the second quarter ended September 30, 2025, compared to a loss of Rs 16 crore in the same period last year.
However, the company’s revenue from operations declined to Rs 782 crore, compared with Rs 818 crore in the year-ago quarter, Wockhardt said in a statement.
The company’s India business contributed Rs 172 crore during the quarter, reflecting a 3 per cent growth compared to the previous year, it added. The UK business generated Rs 313 crore, a growth of 4 per cent compared to the previous year, PTI reported.
Besides, the Ireland business stood at Rs 59 crore in the second quarter with a growth of 40 per cent compared to the previous year, it added.
"We see significant scale up and advancing our leadership in the Biotech diabetes segment on the back of new partnerships in the Emerging markets and India, entry into new markets like Russia and Malaysia as we commit to offer affordable Insulin globally,” it said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.